Skip to content

Author

Antonio Lupia

We have 3 of 47 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Dual inhibitors of SARS-CoV-2 Nsp13 helicase functions with broad anti-hCoV activity and combination effects with approved antivirals.

The SARS-CoV-2 non-structural protein 13 (nsp13) is a highly conserved helicase essential for viral replication and immune evasion. Its conservation across coronaviruses makes it an attractive target for the development of broad-spectrum antiviral agents. Hence, we rationally designed and synthesised 42 novel 2-iminoth...

Erica Sanna, A. Corona, S. Distinto et al. · 0 citations
Open access Aug 2026

The natural coumarin 7-methoxy-8-isopentenyloxycoumarin alleviates LPS-induced inflammation by suppressing NF-κB and the MAPK/AP-1 pathways and accelerating COX-2 proteasomal degradation.

In vivo administration of 7MI dramatically improved survival rate and mitigated multi-organ damage in a murine model of fatal sepsis, highlighting its potential as a lead compound for LPS-associated inflammatory disorders.

Shiu-Wen Huang, Hsiu-Chen Chen, Antonio Lupia et al. · 0 citations
Open access Sep 2026

A combination of MD-derived pharmacophores and structure-based strategy identifies dual allosteric inhibitors of NS2B-NS3 proteases in Zika and West Nile viruses.

This integrated computer-aided drug design (CADD) strategy demonstrates the power of dynamic, structure-based pharmacophores to uncover novel allosteric inhibitors and accelerate antiviral drug repurposing.

A. Lupia, Salvatore Nieddu, Laura Demuru et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.